天新药业(603235) - 2024 Q1 - 季度财报

Revenue and Profit - Revenue for Q1 2024 was CNY 494,498,107.04, a decrease of 14.46% compared to Q1 2023[19] - Net profit attributable to shareholders for Q1 2024 was CNY 147,549,004.33, an increase of 35.87% year-over-year[19] - Net profit excluding non-recurring gains and losses for Q1 2024 was CNY 136,315,268.67, up 33.53% from the previous year[19] - Total operating income for Q1 2024 was CNY 497,412,857.03, compared to CNY 578,385,715.56 in Q1 2023[3] - The net profit attributable to shareholders increased by 35.87% due to higher product sales prices[23] - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 33.53%, driven by increased financial income and foreign exchange gains[23] - The comprehensive income total for Q1 2024 was CNY 147,549,004.33, compared to CNY 108,598,608.80 in Q1 2023, an increase of about 36%[31] - The net profit for Q1 2024 was 147,549,004.33, an increase from 108,598,608.80 in Q1 2023, representing a growth of approximately 36%[48] Operating Performance - Operating cash flow for Q1 2024 was CNY 93,913,720.58, down 48.14% compared to Q1 2023[19] - Operating profit for Q1 2024 was CNY 174,007,082.03, an increase from CNY 135,418,692.30 in Q1 2023[6] - The net cash flow from operating activities decreased by 48.14%, primarily due to reduced cash received from sales and decreased government subsidies[23] - The total revenue from sales of goods and services received in Q1 2024 was 385,278,707.63, compared to 492,513,431.35 in Q1 2023, indicating a decrease of about 22%[49] - The operating profit for Q1 2024 was 176,366,401.91, up from 130,730,911.51 in Q1 2023, reflecting a growth of approximately 35%[48] Expenses and Costs - Total operating costs for Q1 2024 were CNY 329,541,762.38, compared to CNY 454,331,911.17 in Q1 2023, a decrease of about 27.5%[29] - Research and development expenses for Q1 2024 were CNY 9,686,583.82, up from CNY 6,552,836.78 in Q1 2023[3] - Research and development expenses increased to CNY 22,774,738.56 in Q1 2024 from CNY 16,067,191.19 in Q1 2023, reflecting a growth of approximately 41.5%[29] - The company reported a credit impairment loss of -2,357,578.37 in Q1 2024, compared to -530,472.83 in Q1 2023, indicating a significant increase in credit losses[48] - The total non-operating income for Q1 2024 was 14,019.71, while non-operating expenses were 644,101.44, leading to a net non-operating loss[48] Cash and Assets - Cash and cash equivalents at the end of Q1 2024 were CNY 2,309,350,155.08, compared to CNY 2,268,618,703.45 at the end of Q1 2023[12] - The company reported a net increase in cash and cash equivalents of CNY 72,894,170.25 for Q1 2024[12] - The total current assets amounted to RMB 3,464,954,982.88, an increase from RMB 3,335,861,550.81 as of December 31, 2023, representing a growth of approximately 3.9%[52] - The cash and cash equivalents increased to RMB 2,309,350,155.08 from RMB 2,236,455,984.83, reflecting a rise of about 3.2%[52] - Accounts receivable rose to RMB 281,997,202.45 from RMB 244,066,164.59, marking an increase of approximately 15.5%[52] - Inventory decreased to RMB 424,688,852.07 from RMB 484,029,445.11, indicating a decline of about 12.3%[52] - Total non-current assets reached RMB 1,768,709,411.82, up from RMB 1,745,450,961.61, which is an increase of around 1.4%[54] - The total assets of the company as of March 31, 2024, were RMB 5,233,664,394.70, compared to RMB 5,081,312,512.42 at the end of 2023, reflecting a growth of approximately 3.0%[55] - Total liabilities increased to RMB 840,328,125.47 from RMB 809,423,974.11, representing a rise of about 3.0%[55] - The total equity of the company as of March 31, 2024, was RMB 4,393,336,269.23, up from RMB 4,271,888,538.31, indicating an increase of approximately 2.8%[55] Financing Activities - The company reported a short-term loan of RMB 200,000,000.00 as of March 31, 2024, compared to RMB 100,072,222.22 at the end of 2023, which is a significant increase of 99.3%[54] - The company received $120,000,000.00 in cash from borrowings during the financing activities[63] - The cash outflow from financing activities totaled $29,252,362.55, resulting in a net cash flow of $90,747,637.45 from financing activities[64] Shareholder Information - Basic earnings per share for Q1 2024 was CNY 0.34, reflecting a 36.00% increase year-over-year[19] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.34, up from CNY 0.25 in Q1 2023, indicating a growth of 36%[31] - The weighted average return on equity increased to 3.43%, up by 0.79 percentage points compared to the end of the previous year[36] - The company's retained earnings increased to 1,736,924,833.80 from 1,589,375,829.47, showing a growth of approximately 9.25%[45] Market and Strategic Developments - The company has not reported any significant new product launches or technological advancements during this quarter[41] - There were no mergers or acquisitions reported in the current quarter, and the company continues to focus on its existing market strategies[41]